Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 17, 2026
TickeronGET DAILY SIGNALS
SS Innovations International (SSII): Aiming for a +48% Rebound Toward $2.00

SS Innovations International (SSII): Aiming for a +48% Rebound Toward $2.00

Key Takeaways

  • The central target here is $2.00, a technical fallback level based on recent trading ranges rather than any broad analyst view, pointing to roughly a 48% gain from the latest close of $1.35.
  • This is not an average analyst price target. Only one published target exists — $7.00 from Loop Capital (June 2026) — too limited for a true consensus and noted only for context.
  • SS Innovations International, Inc. (SSII), focused on surgical robotics, has dropped about 80% from its 52-week high of $6.79 and carries a going-concern warning.
  • Positive elements include growth in the SSi Mantra installed base (238 systems in 12 countries and over 14,000 procedures) along with solid revenue expansion, with trailing 12-month revenue near $52 million.
  • Key risks center on widening losses, ongoing cash burn, heavy reliance on India (93% of first-half 2026 revenue), and potential financing or dilution needs.
  • For additional details on this name, check its Major News, Today's Price Move, Forecast, and Earnings pages.

Analyst Coverage and How the $2.00 Target Was Set

SSII represents common stock in SS Innovations International, Inc., a company developing the SSi Mantra surgical-robotic system. Coverage remains sparse for this micro-cap. The sole dated price target is the $7.00 level from Loop Capital (analyst Alex Nowak) issued with a Buy rating on June 3, 2026. Weiss Ratings has kept a "sell (e+)" stance and Wall Street Zen shifted to "hold," though neither provides a price goal.

A lone target does not create a reliable consensus, so $7.00 is not treated as the main benchmark. Instead, the $2.00 figure draws from technical structure: shares held in the $2.30–$2.45 zone through late October 2026 before the November drop, positioning $2.00 as a round-number recovery point back toward that area. It serves as a technical reference rather than an analyst projection.

Current Market Position and Path to the Target

The stock closed at $1.35 on November 16, 2026, down roughly 18.7% that day and near the bottom of its 52-week range from $1.26 to $6.79. A move to $2.00 would mean a gain of about 48%, described as substantial given the prolonged downtrend. Even then, shares would remain well below the 2025 peak and under the 50-day moving average near $2.64 and 200-day average around $3.72.

Fundamentals present challenges. Revenue is expanding rapidly, with trailing 12-month figures near $52 million and strong year-over-year gains, yet the company stays unprofitable with trailing EPS around -$0.06 and negative operating cash flow. Management has noted that current cash may fall short for the next 12 months, raising substantial doubt about continuing as a going concern. Progress toward $2.00 would hinge more on renewed financing and execution confidence than earnings alone. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

What Could Support a Move Toward the Target

  • Installed-base growth. As of September 2026, 238 systems were installed across 12 countries with more than 14,000 procedures completed, building a base for recurring instrument and service revenue.
  • Revenue momentum. First-half 2026 revenue climbed to $25 million from $15.1 million the prior year, and the price-to-sales multiple has tightened with the share-price decline.
  • Regulatory optionality. The company submitted its response to an FDA request for more information on the 510(k) filing for SSi Mantra in October 2026, which could open U.S. market access.
  • Leadership and funding steps. Recent appointment of Gary Lo as CFO and equity raised via private placement aim to strengthen the balance sheet and aid global growth.

What Could Prevent the Target From Being Reached

  • Going-concern risk. Management's disclosure that cash and operating income may prove insufficient for the next 12 months stands as the main hurdle, likely requiring further financing or dilution.
  • Persistent losses. The net loss widened to $6.2 million in the first half of 2026, with operating expenses outpacing revenue growth.
  • Geographic concentration. India accounted for 93% of first-half 2026 revenue, exposing results to shifts in local hospital spending and demand.
  • Governance and reporting concerns. Ineffective disclosure controls were reported as of June 30, 2026, and rising customer-financing receivables add working-capital strain.

Technical Levels and Market Structure

The stock remains in a long-term downtrend, trading below both the 50-day moving average near $2.64 and 200-day average near $3.72. The $2.00 target sits just under the prior October consolidation zone of roughly $2.30–$2.45, now serving as overhead supply. On the downside, the 52-week low near $1.26 represents key support. A sustained push above $2.00 would next encounter resistance in the $2.30–$2.45 area before any challenge to the declining averages.

Time Horizon and What Investors Should Monitor

Typical analyst targets cover about 12 months, but with only one target available, no clear consensus horizon applies. The $2.00 level carries no fixed timeline. Focus should stay on upcoming quarterly results (next estimated earnings date late November 2026), any financing updates, FDA 510(k) progress, installed-base and procedure figures, and efforts to reduce cash burn. Given the going-concern flag, liquidity details in future filings merit close attention. From what I see, monitoring these elements helps frame the recovery potential.

AI Daily Buy/Sell Signals

I find Tickeron's AI Daily Buy/Sell Signals useful when following names like SSII. The system applies artificial intelligence to track thousands of stocks and ETFs, producing Buy, Sell, or Hold signals drawn from shifting market conditions, technical patterns, and AI analysis. It serves as a complement to other research by helping spot opportunities and trend changes more efficiently. For anyone assessing whether SSII can generate the momentum needed to approach the levels noted earlier, these signals add a data-driven layer to fundamental and technical work.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SSII

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


SSII in -3.05% downward trend, falling for three consecutive days on November 20, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where SSII declined for three days, in 126 of 136 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for SSII turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 33 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.

The Aroon Indicator for SSII entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +11.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where SSII advanced for three days, in 62 of 95 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.

SSII may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.846) is normal, around the industry mean (4.142). P/E Ratio (0.000) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (12.887) is also within normal values, averaging (40.124).

The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. SSII’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SSII’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -36%. For the same stocks of the Industry, the average monthly volume growth was -3% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 49
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry MedicalNursingServices

Industry
N/A
Address
Udyog Vihar, Phase III
Phone
+91 7337553469
Employees
483
Web
https://www.ssinnovations.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.